Transforming CO2 into Fragrances, Fuels, and Medicines
Synthetic micro-organisms capable of converting carbon dioxide into molecules useful to the pharmaceutical, food, and cosmetic industries. This is the promise of synthetic biology, which no longer merely captures CO2—it transforms it into raw material. Research by Professor Adam Arkin at UC Berkeley explores microbial engineering to optimize these conversions, although quantified performance remains variable depending on experimental conditions. In California, the startup Twelve already produces sustainable aviation fuels and chemical materials from industrial emissions captured by its strains. But between laboratory achievement and massive industrialization, the energy and economic equation remains to be solved.
Performance That Redefines Carbon Capture
Temperate forests capture approximately 0.005 to 0.014 grams of CO2 per gram of biomass per day. The most efficient synthetic micro-organisms can achieve significantly higher capture levels under controlled conditions. This efficiency relies on entirely artificial metabolisms, designed to convert CO2 into useful organic compounds without the constraints of classical photosynthesis.
Laboratory-developed strains can function continuously, 24 hours a day, unlike plants that depend on day-night cycles.
Industrial CO2 Becomes Raw Material
Pilot installations directly transform factory emissions into basic chemical products. One ton of industrial CO2 can generate substantial quantities of biomolecules usable in the pharmaceutical, food, or cosmetic industry.
This direct conversion eliminates the costs of transport and storage of captured CO2. Micro-organisms work on-site, connected to factory stacks. Several experimental facilities in the United States already treat emissions from cement plants and steel mills with high conversion rates.
The California-based startup Twelve produces sustainable aviation fuels and chemical materials from CO2 captured by its synthetic strains. Their installation processes significant volumes of CO2 monthly and generates growing revenues. These figures remain modest against 37 billion tons of global emissions, but they demonstrate the commercial viability of the concept.
The Energy Equation Hinders Generalization
Culturing synthetic micro-organisms consumes substantial quantities of electricity per ton of CO2 treated. This consumption equals that of numerous European households. Industrial expansion therefore requires massive renewable energy sources to avoid the paradox of increasing emissions in order to reduce them.
Recent analyses from ETH Zurich suggest that direct air capture costs will reach between 230 and 540 dollars per ton by 2050. This level places the technology above current carbon prices on European markets, which fluctuate between 80 and 120 euros per ton.
The industry is betting on economies of scale to significantly reduce these costs. Technical projections suggest that a plant treating industrial volumes of CO2 could achieve profitability with a high carbon price.
Three Technical Challenges Persist
Biological contamination remains the primary operational obstacle. Synthetic micro-organisms, optimized for CO2 capture, are vulnerable to natural bacteria and fungi. Facilities must maintain costly sterile conditions, which represents a significant portion of operating expenses.
Genetic stability poses a long-term challenge. Synthetic strains can lose their specialized properties after several generations of reproduction. Laboratories are developing real-time genomic monitoring systems to detect these drifts and correct them automatically.
Recovery of finished products complicates industrialization. Extracting biomolecules from microbial cultures requires sophisticated separation processes. These purification steps add a significant portion to production costs and consume additional energy.
Industrialization Progresses
Industrial partnerships are multiplying. TotalEnergies collaborates with the Pasteur Institute to develop strains adapted to refineries. BASF finances research on bio-sourced plastic production from industrial CO2. These alliances accelerate technology transfer toward commercial applications.
Synthetic biology opens an unprecedented avenue for valorizing unavoidable industrial emissions. Technical performance is impressive, but the economic equation remains to be solved. The next pilot installations will determine whether this scientific promise can rival competing technological approaches in the race toward industrial carbon neutrality.
Sources: